Background: Simultaneous detection of HIV 1 and 2 antibodies and HIV-1 p-24 antigen in the 4th generation tests is particularly effective for the identification of early acute HIV infections while maintaining accurate detection of long-established infections.
Objectives: The aim of this study was to evaluate the new 4th generation VITROS HIV Combo test from Ortho-Clinical Diagnostics by comparing its results with those obtained using a 3rd generation HIV 1/2 antibody test (VITROS Anti HIV 1 + 2 from Ortho-Clinical Diagnostics) and a 4th generation test (LIAISON XL HIV Ab/Ag, DiaSorin) currently used in the Microbiology Unit of Legnano Hospital.
Study Design: One thousand and three samples of the normal daily routine (Group 1) were analyzed simultaneously with the three systems. The concordant and discordant sample results were further tested using Western blot and HIV-RNA assay (Roche). One hundred samples (Group 2) of known HIV positive subjects (63 of subtype B, 37 subtype non-B, and 51 with positive viraemia) and 50 samples (Group 3) with indeterminate Western blot were also examined using the three systems. From Group 3, 24 samples were collected from patients diagnosed with acute infection.
Results: The overall agreement between the three systems was 99.4% (99.5% in group 1, 100% in group 2 and 96.6% in group 3) with a coefficient Fleiss Kappa of 0.9814. Notably, the VITROS HIV Combo test was positive in all known HIV positive samples of group 2 without any statistically significant difference in the values of the sample/cut off ratios between the B and non-B subtypes and between the positive and negative viraemia samples in established infections. The VITROS HIV Combo test was also positive in all samples of patients with acute infection in group 3.
Conclusions: The VITROS HIV Combo test has shown comparable performance to the other two assays in use of 3rd and 4th generation tests and is able to correctly identify both acute and established HIV infections independently of viraemia and HIV subtype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcv.2018.09.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the Vitros® Anti-T. cruzi assay for its incorporation into the infection diagnostic algorithm.
Heliyon
December 2024
Microbiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Background And Objective: Serological screening for Chagas disease (CD) in Latin American adults living in Europe is a cost-effective strategy for transmission prevention. The World Health Organization recommends two different serological tests including native and recombinant antigens for IgG detection. In Spain, most commercialized native tests require manual processing.
View Article and Find Full Text PDFSeroprevalence of hepatitis C, hepatitis B, hiv and syphilis among blood donors at a tertiary care hospital in Mogadishu-Somalia in 2020-2022: a retrospective study.
BMC Public Health
September 2024
Department of Education, Mogadishu Somalia Turkey Recep Tayyip Erdogan Training and Research Hospital, Mogadishu, Somalia.
Article Synopsis
- * Researchers examined 109,385 donor samples using ELISA tests and found very low positivity rates: 0.6% for HBV, 0.01% for HCV, 0.03% for HIV, and 0.3% for syphilis.
- * The conclusion emphasizes that while the seroprevalence rates for these infections are low, it is crucial to maintain stringent donor selection and screening processes to ensure blood safety for recipients.
Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel.
Access Microbiol
February 2024
Respiratory Viruses Immunology Team, CDC, Atlanta, Georgia, USA.
Article Synopsis
- SARS-CoV-2, the virus responsible for COVID-19, was identified in 2019 and has led to a significant global health crisis.
- The study evaluated the effectiveness of various serological tests for detecting SARS-CoV-2 specific antibodies, including in-house ELISA and commercial assays, using samples from confirmed COVID-19 patients and a control group.
- All tests showed high sensitivity (95.4-96.6%) and diagnostic accuracy, but the researchers emphasized the need for independent evaluations to enhance the interpretation of serological test results.
Evaluation and experience from routine use of chemiluminescence assays for serological screening of blood and plasma donations on the Alinity s system and the Alinity i system, two new fully-automated immunoassay systems in Poland.
Pract Lab Med
March 2024
Institute of Hematology and Transfusion Medicine (IHTM), Department of Virology, Warsaw, Poland.
In Poland, independent evaluations under the auspices of the Institute of Hematology and Transfusion Medicine (IHTM) are mandated for any new device, assay, systems for screening samples from whole blood and plasma donors prior to implementation by Blood Transfusion Center (BTC). In last 5 years, two new systems were introduced to the market by Abbott GmbH, namely the Alinity s and the Alinity i. The evaluations performed for these two systems included the assessment of sensitivity, specificity and precision for each of the four mandatory serological screening markers in Poland: Hepatitis B Surface Antigen (HBsAg), Hepatitis C virus antibodies (Anti-HCV), HIV antibodies (anti-HIV) and Syphilis antibodies (anti- anti-TP).
View Article and Find Full Text PDFValidation of a Novel Fluorescent Lateral Flow Assay for Rapid Qualitative and Quantitative Assessment of Total Anti-SARS-CoV-2 S-RBD Binding Antibody Units (BAU) from Plasma or Fingerstick Whole-Blood of COVID-19 Vaccinees.
Vaccines (Basel)
August 2022
Biomedical Research Center, Qatar University, Doha 2713, Qatar.
Background: Limited commercial LFA assays are available to provide a reliable quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim: This study aimed to evaluate the performance of the fluorescence LFA FinecareTM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113) against the following reference methods: (i) the FDA-approved GenScript surrogate virus-neutralizing assay (sVNT); and (ii) three highly performing automated immunoassays: BioMérieux VIDAS®3, Ortho VITROS®, and Mindray CL-900i®.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!